Couple Smiling -Windtree Hero

WELCOME TO WINDTREE THERAPEUTICS

DELIVERING INNOVATIVE TREATMENT AND HOPE FOR PATIENTS

Windtree Therapeutics is a biopharmaceutical company focused on oncology and cardiovascular treatments intended to address markets with significant unmet need (NASDAQ: WINT)

Istaroxime is a firstinclass dual mechanism therapy designed to improve cardiac function by increasing both systolic contractions of the heart as well as diastolic relaxation through SERCA2a activation and Na+/K+ ATPase inhibition.

SERCA2a Activators

SERCA2a Activators

Our heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activators which activate SERCA2a. This research program is evaluating these preclinical product candidates, including oral and intravenous SERCA2a activator heart failure compounds. As potential oral agents, these candidates would be developed for chronic heart failure.

Next Generation Oral SERCA2a Activators Platform has Potential for both Major Types of HF in Acute and Chronic Therapy
atypical protein kinase c iota aPKCi inhibitor
Oncology Asset aPKCi inhibitor topical VAR-101 and oral VAR-102

“Our mission is clear – to support patients in crisis situations by arming the healthcare providers with therapies that significantly improve upon current standards of care. We are developing important critical care innovations that have the potential to address some of the most significant unmet medical needs and will strive to deliver them responsibly with unrelenting attention to quality and access to care.”

— Craig Fraser